InterMune Closes Collaboration Agreement With Roche

06-Nov-2006

InterMune, Inc. announced that on October 30, 2006, it successfully closed its Exclusive License and Collaboration Agreement with Roche for the exclusive worldwide development and commercialization of InterMune's hepatitis C virus (HCV) protease inhibitor program. The parties received notice of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, on October 30, 2006.

Having closed the transaction, InterMune will receive an upfront payment of $60 million. According to the compnay, Roche is now funding 67% of the global development costs associated with ITMN-191, InterMune's lead HCV protease inhibitor drug candidate. Assuming the successful development and commercialization of ITMN-191 in the U.S. and other countries, InterMune could receive up to $470 million in milestones, including a potential $35 million within the next 12 months.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances